S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
NFLX   293.35 (+2.47%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
NFLX   293.35 (+2.47%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

China Biologic Products Stock Price, News & Analysis (NASDAQ:CBPO)

$115.63
-0.34 (-0.29 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$114.99
Now: $115.63
$116.21
50-Day Range
$99.25
MA: $108.78
$116.35
52-Week Range
$60.08
Now: $115.63
$116.63
Volume2,421 shs
Average Volume243,541 shs
Market Capitalization$4.55 billion
P/E Ratio28.86
Dividend YieldN/A
Beta1.2
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$466.88 million
Cash Flow$5.13 per share
Book Value$55.68 per share

Profitability

Net Income$128.06 million

Miscellaneous

Employees2,187
Market Cap$4.55 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.


China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings Inc (NASDAQ:CBPO) released its earnings results on Monday, August, 5th. The biopharmaceutical company reported $1.24 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.03 by $0.21. The biopharmaceutical company had revenue of $135.70 million for the quarter. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The business's quarterly revenue was up 12.7% compared to the same quarter last year. During the same period last year, the business earned $1.17 EPS. View China Biologic Products' Earnings History.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for China Biologic Products.

What guidance has China Biologic Products issued on next quarter's earnings?

China Biologic Products issued an update on its FY19 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of $4.18-4.26 for the period, compared to the Thomson Reuters consensus estimate of $4.07.

What price target have analysts set for CBPO?

3 equities research analysts have issued 12 month price targets for China Biologic Products' stock. Their predictions range from $62.00 to $88.00. On average, they anticipate China Biologic Products' stock price to reach $78.00 in the next twelve months. This suggests that the stock has a possible downside of 32.5%. View Analyst Price Targets for China Biologic Products.

What is the consensus analysts' recommendation for China Biologic Products?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.

Has China Biologic Products been receiving favorable news coverage?

Media coverage about CBPO stock has trended negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. China Biologic Products earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for China Biologic Products.

Are investors shorting China Biologic Products?

China Biologic Products saw a decline in short interest in September. As of September 30th, there was short interest totalling 520,700 shares, a decline of 32.5% from the August 30th total of 771,100 shares. Based on an average daily trading volume, of 159,800 shares, the short-interest ratio is presently 3.3 days. Currently, 2.5% of the shares of the company are short sold. View China Biologic Products' Current Options Chain.

Who are some of China Biologic Products' key competitors?

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), Sarepta Therapeutics (SRPT), The Carlyle Group (CG), Gilead Sciences (GILD), GSI Technology (GSIT), ACADIA Pharmaceuticals (ACAD), Amgen (AMGN), Biogen (BIIB), RYB Education (RYB) and Broadcom (AVGO).

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the folowing people:
  • Mr. Ming Yang, Chief Financial Officer (Age 47)
  • Mr. Ming Yin, Sr. VP (Age 41)
  • Ms. Zhijing Liu, Corp. VP (Age 65)
  • Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)
  • Dr. Bing Li Ph.D., CEO & Director (Age 51)

Who are China Biologic Products' major shareholders?

China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.05%). View Institutional Ownership Trends for China Biologic Products.

Which institutional investors are buying China Biologic Products stock?

CBPO stock was bought by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for China Biologic Products.

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $115.63.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $4.55 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.View Additional Information About China Biologic Products.

What is China Biologic Products' official website?

The official website for China Biologic Products is http://www.chinabiologic.com/.

How can I contact China Biologic Products?

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]


MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  413 (Vote Underperform)
Total Votes:  736
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel